Nonspecific endocytosis Endocytosis is an important process in cell uptake of nutrients, regulation of transmembrane kinetics, synaptic vesicle recycling, and so on. Endocytosis can also play an important role in the uptakeRead More…
Uptake and Potential Toxicity Mechanism of Non-Target-Dependent ADC—I
Linker-Unstable Payload Connection Connector-payload instability can cause the payload to be released prematurely into the bloodstream and lead to ADC miss toxicity. The choice of connectors is one of the main driversRead More…
Non-targeted ADC Uptake Matters!
So far, a total of 16 ADC drugs have been approved worldwide, and one (trastuzumab duocarmazine) is still in the stage of applying for listing. In recent years, with the significant increaseRead More…
ADC Combination Therapy: Combining with Immunotherapy
Recently, combining immunotherapy with ADCs has entered clinical research, with growing evidence that ADCs may increase the efficacy of immunotherapy. Its mechanisms are varied, including inducing immunogenic cell death, dendritic cell maturation,Read More…
ADC Combination Therapy: Combining with Targeted Drugs
Compared to standard chemotherapy, ADC (antibody-drug conjugate) improves the therapeutic index, and its activity in patients with selective tumors makes it a potential partner for targeted drugs. Joint strategies can be conceivedRead More…
ADC Combination Therapy: Combining with Chemotherapy
Although ADC drugs have greatly improved the survival benefits of patients, the duration of their objective response or clinical benefits as a monotherapy is limited due to the emergence of drug resistanceRead More…
Platinum-Resistant Ovarian Cancer to Create New Drugs! FDA Approved ADC Elahere
In November 2022, ImmunoGen announced that the Food and Drug Administration (FDA) has accelerated the approval for Elahere (mirvetuximab soravtansine-gynx): a monotherapy for adult patients with epithelial ovarian, fallopian, and primary peritonealRead More…
ADC Panoramic Overview- Endocytosis of ADC Targeting Antigens
CD33 CD33, a 67kda transmembrane glycoprotein receptor, is usually expressed in normal myeloid cells and it is the target of GO because it is preferentially overexpressed in AML cells. The intracellular immunoreceptorRead More…
ADC Panoramic Overview- endocytosis pathway of ADC
Generally speaking, normal endocytosis can be divided into three stages: (1) bud formation; (2) membrane bending and vesicle maturation; and (3) membrane rupture and release into the cytoplasm. Multiple endocytosis pathways overlap,Read More…
ADC Overview: Bioconjugation Technology Ⅲ
Bioconjugation with engineered unnatural amino acids In addition to the sulfur monoclonal antibody technique, the addition of non-standard amino acids (ncAA) provides another possibility for site-specific conjugation. This technique uses amino acidsRead More…